What is the 13F Pro Quality Score for RNXT?

13F Pro ranks RenovoRx, Inc. (RNXT) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View RNXT's current score at https://13fpro.ai/research/RNXT (free sign-up required for the full ranking).

Where does 13F Pro source RNXT data?

All RenovoRx, Inc. fundamentals and ownership data come directly from SEC EDGAR. RenovoRx, Inc. files with the SEC under CIK 1574094. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is RNXT in?

RenovoRx, Inc. (RNXT) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is RNXT research updated on 13F Pro?

RNXT's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

RenovoRx, Inc.(RNXT)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1574094 RNXT stock profile & AI dashboard →

13F Pro Quality Score

Not in ranked universe

Below size threshold

Quality rankings require at least $50M annual revenue or $250M total assets to filter out micro-caps and shell companies. This company reported $1.1M in revenue.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

RNXT Stock Analysis & AI Quality Score

AI stock analysis and institutional research for RenovoRx, Inc. (RNXT), a Healthcare sector company. RNXT is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least $50m annual revenue or $250m total assets to filter out micro-caps and shell companies. this company reported $1.1m in revenue. Based on the latest XBRL financial filings (Q1 2026), RenovoRx, Inc. reports quarterly revenue of $563.0K, net income of $-3.5M, free cash flow of $-3.7M. Top institutional holders of RNXT by reported 13-F value include AIGH Capital Management, Bleichroeder, VANGUARD CAPITAL MANAGEMENT, based on the most recent SEC filings. RNXT trades on the Nasdaq exchange and files with the SEC under CIK 1574094. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate RNXT daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for RenovoRx, Inc. directly from SEC EDGAR.

Revenue

Q1 2026

$563.0K

Net Income

Q1 2026

$-3.5M

Free Cash Flow

Q1 2026

$-3.7M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

+2511.6% YoY

$1.1MFY 2025

FY22 —FY23 —FY24 $43.0KFY25 $1.1M

Net Income

-26.7% YoY

$-11.2MFY 2025

FY22 $-9.9MFY23 $-10.2MFY24 $-8.8MFY25 $-11.2M

Operating Income

-14.0% YoY

$-12.5MFY 2025

FY22 $-9.9MFY23 $-11.4MFY24 $-11.0MFY25 $-12.5M

EPS (Diluted)

+20.0% YoY

$-0.32FY 2025

FY22 $-1.09FY23 $-0.99FY24 $-0.40FY25 $-0.32

Total Assets

-0.3% YoY

$8.1MFY 2025

FY22 $7.3MFY23 $1.5MFY24 $8.1MFY25 $8.1M

Op. Cash Flow

-20.3% YoY

$-11.0MFY 2025

FY22 $-8.8MFY23 $-10.3MFY24 $-9.1MFY25 $-11.0M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Revenue	$1.1M +2511.6%	$43.0K	—	—	—
Net Income	$-11.2M -26.7%	$-8.8M +13.9%	$-10.2M -3.5%	$-9.9M -56.4%	$-6.3M
Operating Income	$-12.5M -14.0%	$-11.0M +3.7%	$-11.4M -14.5%	$-9.9M -75.5%	$-5.7M
EPS (Diluted)	$-0.32 +20.0%	$-0.40 +59.6%	$-0.99 +9.2%	$-1.09	—
Total Assets	$8.1M -0.3%	$8.1M +453.8%	$1.5M -79.8%	$7.3M -55.4%	$16.3M
Operating Cash Flow	$-11.0M -20.3%	$-9.1M +11.0%	$-10.3M -16.4%	$-8.8M -48.9%	$-5.9M

AI Insight: RNXT Financial Trends

RenovoRx generated first reported revenue of $1M in Q1 2026 but cash burn and equity depletion accelerated amid pre-commercial phase.

• Revenue emerged at $1M in Q1 2026 after four quarters of $0M, signaling early commercial traction.

• Operating cash flow deteriorated to -$4M in Q1 2026 from -$2M average in prior quarters.

• Equity recovered to $11M in Q1 2026 from $5M low in Q4 2025, likely from financing activity.

⚠ Net loss widened to -$4M in Q1 2026, largest loss in dataset despite revenue recognition.

⚠ Operating income worsened to -$4M in Q4 2025–Q1 2026 from -$3M baseline, signaling scaling costs.

AI Insight: RNXT Ratio Trends

RenovoRx remains deeply unprofitable with ROE deteriorating to -125.0% in Q1 2026, showing no path to profitability in available data.

• ROE collapsed from -73.6% in Q1 2025 to -125.0% in Q1 2026, indicating shareholder value destruction accelerating.

• ROA worsened from -60.5% in Q1 2025 to -84.9% in Q2 2025, reflecting deteriorating asset efficiency.

⚠ ROIC measured at -94.5% in Q1 2025; subsequent quarters lack ROIC data, limiting visibility into capital deployment.

⚠ No positive operating or net margins recorded across all periods; company burning cash with no disclosed profitability inflection.

Get alerted when RNXT's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for RenovoRx, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of RNXT

AIGH Capital Management LLC
$3.7M3,706,197 sh
Bleichroeder LP
$1.7M1,666,098 sh
VANGUARD CAPITAL MANAGEMENT LLC
$1.5M1,447,177 sh
GEODE CAPITAL MANAGEMENT, LLC
$385.6K381,723 sh
Wealthspire Advisors, LLC
$255.1K252,525 sh
CITADEL ADVISORS LLC
$235.0K232,684 sh
VANGUARD FIDUCIARY TRUST CO
$159.5K157,902 sh
NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO
$100.5K99,460 sh
NIXON PEABODY TRUST CO
$98.1K97,165 sh
Chicago Partners Investment Group LLC
$87.6K92,356 sh

Fund	Value	Shares
AIGH Capital Management LLC	$3.7M	3,706,197
Bleichroeder LP	$1.7M	1,666,098
VANGUARD CAPITAL MANAGEMENT LLC	$1.5M	1,447,177
GEODE CAPITAL MANAGEMENT, LLC	$385.6K	381,723
Wealthspire Advisors, LLC	$255.1K	252,525
CITADEL ADVISORS LLC	$235.0K	232,684
VANGUARD FIDUCIARY TRUST CO	$159.5K	157,902
NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO	$100.5K	99,460
NIXON PEABODY TRUST CO	$98.1K	97,165
Chicago Partners Investment Group LLC	$87.6K	92,356

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put RNXT on your watchlist

Track score changes the day RenovoRx, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is RNXT a good stock to buy?

13F Pro's AI-powered analysis of RenovoRx, Inc. (RNXT) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for RNXT are available on the RNXT stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own RNXT?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling RNXT. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of RenovoRx, Inc.'s investment landscape.